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ABSTRACT 
 Ras is frequently mutated in cancer; however, there is a lack of consensus in the 
literature regarding the cancer mutation frequency of Ras with quoted values varying 
from 10-30%. This variability is at least in part due to the selective aggregation of data 
from different databases and the dominant influence of particular cancer types and 
particular Ras isoforms within these datasets. In order to provide a more definitive 
figure for Ras mutation frequency in cancer, we have cross-referenced the data in all 
major publicly accessible cancer mutation databases to determine reliable mutation 
frequency values for each Ras isoform in all major cancer types. These percentages 
have then been applied to current US cancer incidence statistics to estimate the 
number of new patients each year that have Ras-mutant cancers. We find that ~19% 
of cancer patients harbor Ras mutations; equivalent to ~3.4 million new cases per year 
worldwide. We discuss the Ras isoform and mutation-specific trends evident within 
the datasets that are relevant to current Ras-targeted therapies. 
 
INTRODUCTION 
 Ras proteins activate signaling networks controlling cell proliferation, differentiation 
and survival (1). They are encoded by three ubiquitously expressed genes, HRAS, 
KRAS and NRAS, that share significant sequence homology and largely overlapping 
functions (2). Ras proteins cycle between an inactive GDP-bound conformation and 
an active GTP-bound conformation. Activation is facilitated by guanine nucleotide 
exchange factors (GEFs), and inactivating GTP hydrolysis is enhanced by GTPase-
activating proteins (GAPs). Ras activation causes a conformational change that allows 
engagement with more than 20 different proteins from 10 effector families (3). The 
most intensively studied of these from a cancer and therapeutic perspective have been 
the RAF and PtdIns-3 kinase families. Activated Ras concentrates effector proteins 
into plasma membrane signaling nanoclusters where they can interact with necessary 
proteins and lipids to control downstream pathways (4). Mutations of Ras that render 
the protein constitutively active are widely observed in cancer; however, there are 
distinctive patterns in the mutation frequencies associated with each Ras gene and 
cancer type (5).   
 
ONCOGENIC RAS 
 Gain-of-function missense mutations promote oncogenesis with almost all detected 
in patients clustering in three hotspots at codons 12, 13 and 61 (5). These result in 
enhanced GTP binding due to fast exchange of nucleotide and/or impairment of GAP 
binding (6). Although these mutants are all activating, they are not equal in their 
oncogenic potential and differences in patient survival are associated with different 
Ras mutants (7-11). Mutation-specific oncogenesis was clearly demonstrated in vivo 
using a library CRISPR gene-editing approach that allowed 12 different activating 
codon 12 and 13 mutations of KRAS to be simultaneously compared in each mouse 
and found that only five of these mutants resulted in the development of lung tumors 
(12). The frequency of individual mutations in patients also varies across tissue types 
and between isoforms suggesting contextual influences that determine which isoform-
mutation combinations have a selective advantage in different cancer types (5).  
 The interplay between three main factors determines whether conditions are 
permissive for initiation and progression of Ras-dependent oncogenesis and might 
explain why specific Ras isoforms and mutations are associated with distinct cancer 
types (5). The first is Ras dosage that is defined by expression levels and relative 
activation state (13). The proportion of a Ras population that is GTP-bound varies from 
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30-90% dependent upon which mutation is present (14). Furthermore, the stability of 
the active state can vary dependent on whether the mutant is fast-cycling or GAP-
insensitive (6). Together with the fact that Ras expression levels vary over 100-fold 
between isoforms and across tissues (15), this means that significant differences in 
Ras signaling capacity can result depending on the tissue/isoform/mutation 
combination. Only a subset of these combinations will be optimal since too much Ras 
signaling promotes senescence or cell death whilst too little fails to initiate 
tumorigenesis (16-18). Importantly, the narrow range of permissive signaling capacity 
is subject to change over time to facilitate tumor progression and resistance to 
therapeutics (19).  
 The second factor is signal specificity associated with each Ras isoform and their 
individual mutations. The extent to which Ras isoforms display differential coupling to 
effector pathways is not well understood. It is also confounded by differences in 
expression/dosing; however, in vivo experiments expressing Ras isoforms from the 
same genetic locus to avoid dosage influences still revealed that Ras isoforms cannot 
fully recapitulate the functions of each other (20,21). Isoform-specific signaling is 
thought to be mediated by differential intracellular localisation that favors preferential 
coupling to specific effector pathways (4,22,23), and by distinct biochemical properties 
imparted by allosteric lobe sequence variations between each isoform (24). Recent in 
vitro analysis revealed distinct binding preferences for Ras-Raf interactions with BRAF 
binding being highly selective for KRAS whilst CRAF was critical for HRAS-mediated 
MAP kinase signaling (25). Mutational-specificity is also important for Ras biology 
(12,26-29), and structural and biochemical features underpinning mutational 
differences in nucleotide cycling, allosteric regulation and GEF, GAP and effector 
interactions are now being defined (14,25,28,30-32).  
 The final factor is cellular and tissue context that contributes the genetic, epigenetic 
and proteomic landscapes in which Ras networks operate. This heterogeneity can 
result in different proliferative potential depending on the capacity of the oncogene to 
engage the subset of drivers in that cell or tissue (28,33,34). Ras dosing and signaling 
specificity titrated against these backgrounds will favor selection of different Ras 
variant combinations in each tissue. Cellular context is also important: an example of 
this was seen in the spatial and cell type-specific variation in MAP kinase activation in 
KRASG12V mutated mouse colon that was shaped by cell type differences in 
expression of regulatory proteins of the MAP kinase pathway (35).  
 Our understanding of cancer is facilitated by observing patterns found in cancer 
mutation databases. Those data have highlighted the isoform/mutation combinations 
most frequently seen in each tissue and this has helped to inform the development 
and testing of potential Ras-targeted therapies in appropriate patient groups. 
However, it is also important to note that the lack of consensus among these datasets 
that can result in incorrect estimates of the true disease burden associated with each 
Ras isoform. 
 
CANCER MUTATION DATABASES 
 We incorporate four leading cancer mutation databases into our analyses. The 
largest of these is the Catalogue of Somatic Mutations in Cancer (COSMIC), that 
contains manually curated data from the cancer literature comprising ~9.7 million 
coding mutations from ~1.4 million samples (including ~34,000 whole genomes; (36)). 
The most refined database is The Cancer Genome Atlas (TCGA) that has molecularly 
characterised tumor samples from ~11,300 patients representing 33 cancer types. All 
samples in TCGA have been subject to comprehensive genomic, epigenomic, 
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transcriptomic and proteomic analysis to better understand the oncogenic systems 
biology of molecular subtypes of cancer (37). The co-ordinated management within 
the TCGA Program means that verification and quality control of sample type is also 
likely to be the most consistent versus larger datasets derived from multiple 
independent studies. The Memorial Sloan Kettering Cancer Centre (MSKCC) 
cBioPortal facilitates meta-analysis of TCGA and ~130 other datasets comprising 
~40,000 samples (38). The International Cancer Genome Consortium (ICGC) data 
portal performs a similar function with multi-omic data for 22 cancer types currently 
curated from ~24,000 samples derived from patients from around the world (39). There 
is overlap in the data present within each database, with almost all TCGA data also 
found within the cBioPortal data portal, ~50% of TCGA data are present within the 
ICGC data portal and all of the data found in TCGA, cBioPortal and ICGC is collated 
within COSMIC (Figure 1). 
 With such rich and integrated datasets available, it might seem surprising that there 
is still no consensus on the disease burden associated with a major oncogene such 
as mutant Ras. For example, 11.6% of TCGA samples, 17.5% of cBioPortal samples, 
19.3% of ICGC samples and 24.8% of COSMIC samples are Ras mutant (Figure 1). 
These differences are driven by the different priorities underpinning sample curation. 
COSMIC collates widely from the cancer literature and includes a high proportion of 
tissues such as colon and lung that contain high percentages of KRAS mutations 
(Figure 1B). In contrast, the other datasets consist of studies where Ras mutation 
status was not a factor in their collection and consequently contain larger proportions 
of breast, brain, kidney and liver samples where Ras mutations are rarely observed.  
 In fact, none of the percentages accurately reflect Ras disease burden since none 
of the datasets accurately recapitulate the relative frequency of each disease in the 
patient population. An example of this is seen in the TCGA dataset, where the ten 
rarest cancers representing 2.7% of new cases/year in the US account for ~20% of 
TCGA samples. Given this, how should the datasets be used best to understand Ras 
mutation patterns? It seems likely that the sheer volume of Ras mutant samples within 
the COSMIC dataset (Figure 1), means that for many cancer types broadly accurate 
conclusions can be drawn regarding the association of particular Ras isoforms and 
the types of mutations observed. In contrast, the smaller datasets are particularly 
suited to comparative analysis of genome-wide changes and genetic associations with 
mutant Ras.  
 
RAS PATTERNS ACROSS DATASETS 
 Comparison of KRAS mutation data for major KRAS-associated cancers illustrates 
the challenge of reaching a consensus across the datasets (Supplementary Table 1). 
For example, colorectal cancer exhibits KRAS mutation frequencies of ~33% in the 
COSMIC dataset comprising ~75,000 tested samples. The frequencies of 40-45% 
suggested by the other datasets are based on small sample sizes of fewer than 500. 
Notably however, the private Foundation Medicine (FM) dataset comprising 13,336 
colorectal samples reports a KRAS mutation frequency of ~50% (40). This may be 
due to higher sensitivity of the recent genetic screening methods employed by FM 
versus the long-term aggregate data in COSMIC. A second point of difference is that 
the samples within the FM dataset were from patients that presented with advanced 
metastatic disease in contrast to the heterogeneity of samples collated in COSMIC 
that were derived from a wide range of studies. For lung cancer, similar disparities are 
evident with COSMIC reporting lower percentages of ~21% and the small-scale 
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datasets giving intermediate values compared to a recent large-scale FM study that 
found that 31% of 5,749 lung adenocarcinoma samples were KRAS mutant (41).  
 The collated pancreatic data reveals a consistent anomaly: according to literature 
sources 90-98% of pancreatic cancers are KRAS mutated (1,3,42); while most 
datasets contain lower values of 70-75% (Supplementary Table 1). The stroma of 
pancreatic ductal adenocarcinomas (PDACs) are extensively infiltrated with cancer-
associated fibroblasts that are not Ras mutant (43). It seems likely that the lower 
estimates across the datasets are confounded by stromal sampling resulting in 
reduced sensitivity for positively identifying KRAS mutations in the small 
subpopulations of cancer cells present. Consistent with this, a recent large-scale 
cancer genetics study by Foundation Medicine of 3,594 primary and metastatic PDAC 
samples where a required threshold of cancer cell content was rigorously verified in 
each sample reported that 88% of samples contain KRAS mutations (44).  
 Where publicly available datasets such as the TCGA excel is in multi-gene 
comparisons and in the integrated analysis of a wide range of types of genetic 
changes. The Pan-Cancer Atlas used TCGA data to define the molecular subtypes of 
cancer and to generate deep understanding of the genetic programmes associated 
with driving different cancer types (45). Analysis of 85 genes within the immediate 
receptor tyrosine kinase (RTK)-Ras network (37), reveals a wide range of Ras 
pathway dependencies ranging from 30-96% of samples across the TCGA cancer 
types (Supplementary Figure 1). Some of these such as pancreatic cancer (PAAD in 
TCGA terminology) are highly linked to Ras mutation; however, most cancers exhibit 
activating genetic changes in the Ras network independently of mutant Ras. Targeting 
Ras and Ras network genes is clearly relevant in nearly all cancer types, even those 
where Ras mutations are rarely found.  
 Amplification of non-mutated Ras is a feature of a subset of cancers including 
esophageal (ESCA), stomach (STAD), ovarian (OV) and testicular (TGCT) where it 
represents the dominant type of Ras genetic change (Supplementary Figure 1). In 
each of these cases KRAS is by far the most frequently amplified and the most 
frequently mutated Ras isoform. We haven’t formally checked whether it is the wild 
type or mutant allele that is amplified; however, in these specific cancer types where 
amplification is seen more often than mutation, at least a subset of these events will 
be in the wild type allele. Changes in Ras dosage are associated with progression and 
response to therapy (19); and the deletions and amplifications observed in some 
cancer types may reflect this. Copy number analysis reveals that the Ras isoforms 
display distinct patterns, with KRAS typically amplified whilst HRAS is more often 
deleted when copy number changes occur (Supplementary Table 2b). Some of these 
changes appear to be reciprocal; for example, in squamous cell lung cancer (LUSC), 
HRAS and NRAS exhibit copy number losses whereas KRAS increases 
(Supplementary Table 2b). Alternatively, in bladder (BLCA), ovarian (OV) and 
testicular (TCGT) cancer, HRAS is decreased but both NRAS and KRAS show a clear 
tendency for increasing copy number. Together, these suggest that some interesting 
isoform-specific biology may be at play that could be worth further investigation. 
 Thus the lack of consensus at the tissue level remains problematic; however, the 
major themes within each dataset in terms of preferential coupling of particular Ras 
isoforms to specific cancer types and the patterns of mutations are consistent across 
all datasets. In the absence of access to large private cancer genetics datasets that 
have the benefits of scale, consistently high quality of curation and comprehensive 
genomic screening, we will use the COSMIC dataset together with selected publicly 
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available data from the Foundation Medicine database to collate Ras isoform 
mutations patterns across a wide range of cancer types. 
 
RAS MUTATION FREQUENCIES IN CANCER 
 In order to estimate Ras disease burden, it is necessary to convert the Ras mutation 
frequencies found in cancer genetics databases into patient numbers based on current 
cancer incidence data. We have collated frequencies for a wide range of cancers from 
all four databases (COSMIC, cBioPortal, ICGC and TCGA; Supplementary Table 2). 
The data are derived from formally verified cancer types rather than samples with only 
a generic tissue-based categorization and we have used the TCGA naming system 
where relevant to facilitate cross-comparison between databases. Data from 
COSMIC, together with publicly available Foundation Medicine data for all three Ras 
isoforms in colorectal adenocarcinoma (COAD, READ) and KRAS mutation 
frequencies in lung (LUAD) and pancreatic (PAAD) adenocarcinomas are presented 
in Table 1. In 2018 the American Cancer Society estimated that ~1.7 million new cases 
of cancer were diagnosed in the United States (46). The 29 cancer types presented in 
Table 1 represent ~80% coverage of United States cancer cases. Note that we have 
not included non-melanoma skin cancers in Table 1 since they almost always present 
as benign, they are typically under-reported in cancer statistics and they are not 
included in global cancer incidence reports. 
 We estimate that ~19% of cancer patients will harbor a Ras mutation; this is 
equivalent to ~260,000 new cases per year in the United States. Globally, there are 
currently ~18 million new cancer diagnoses per year (47). Whilst acknowledging that 
the incidence of different cancer types varies around the world, a simple extrapolation 
of our observations suggests that there are ~3.4 million new cancer cases worldwide 
per year with a Ras mutation. KRAS is the most frequently mutated of the three Ras 
isoforms in 19 out of the 29 cancer types in Table 1 and is responsible for 75% of Ras 
mutant cancers. NRAS (17% of patients) and HRAS (7%) show strong coupling to only 
a small subset of cancer types. Isoform-specific coupling is particularly evident for 
major KRAS cancer types and for NRAS in melanoma (SKCM; Table 1). In contrast, 
thyroid cancer sub-types (THCAA, THCAF) are notable for displaying high levels of 
mutation in all three Ras isoforms. 
 Although KRAS is the major cancer-causing isoform, patient numbers for the other 
Ras isoforms are still significant and translate into ~230,000 patients globally for HRAS 
and ~560,000 for NRAS. This highlights the importance of targeting all isoforms and 
not just the current concentration on developing KRAS-targeted therapies. Farnesyl 
transferase inhibitors (FTIs) that failed clinical trials more than 20 years ago (48) are 
enjoying a renaissance due to personalized medicine approaches. KRAS and NRAS 
do not respond to FTIs; however, HRAS is sensitive (48). Ras mutation profiling means 
that suitable patients can now be identified and the FTI Tipifarnib is currently 
progressing through Phase 2 clinical trials for use in HRAS mutant head and neck, 
leukemia, lymphoma and thyroid cancers (ClinicalTrials.Gov). Whilst most of these 
cancers represent obvious choices for use of FTIs (Table 1), there are appreciable 
numbers of potential beneficiaries across a wide range of other cancer types. This 
includes breast cancer where we estimate that globally there are ~17,000 new cases 
per year that will harbor mutant HRAS. In addition to targeted use of existing FTIs, an 
exciting new FTI has recently been developed that overcomes KRAS resistance and 
potentially opens the way to pan-Ras inhibition (49). 
 Examining mutation-specific patterns also reveals patterns associated with distinct 
tissue types (Supplementary Table 3). For example, KRAS codon 13 mutations are 
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particularly associated with the gastro-intestinal tract and some blood cancers where 
rare mutations of A146 are also mostly observed. There are 19 different activating 
codon 12, 13 or 61 mutations that can be created in each isoform by a single base 
change. Five mutations (G12D, G12V, G12C, G13D and Q61R) account for 70% of 
all Ras-mutant patients. G12C mutations are frequently found in lung cancer due to 
G:C>T:A transversions associated with bulky adducts generated by the mutagens in 
tobacco smoke (50). Chemical inhibitors of G12C-mutated KRAS have been 
developed (51-53). These compounds preferentially bind to GDP-bound KRAS and 
prevent exchange for GTP and interaction with effectors. Compounds developed by 
Mirati, Wellspring, Janssen, and Amgen have now entered Phase I/II clinical trials and 
Amgen recently reported the initial results of their trials with AMG 510 where it was 
tolerated by patients and stabilized or partially regressed their non-small cell lung 
tumors (54). Associated in vivo studies revealed a synergy with immunotherapy and 
excitingly 9 out of 10 mice showed complete and curative tumor regression when AMG 
510 was used in combination with anti-PD-1. Whilst lung cancer has been the focus 
of these trials due to the smoking-associated prevalence of KRASG12C, many other 
cancer types contain appreciable numbers of potential beneficiaries of treatment 
(Supplementary Table 3), especially when considered on a global scale. It is also 
important to be able to target other mutations such as G12V and G12D that each have 
a 2-3-fold higher disease burden than G12C. Several compounds targeting these 
other mutations are now in development and entering trials.  
 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 We have determined the global disease burden associated with Ras mutations for 
different cancer types. ~19% of cancer patients harbor Ras mutations with KRAS 
responsible for 75% of that number. Our meta-analysis revealed the differences in 
sampling and interpretation that underlie the lack of consensus that has prevailed to 
date. Converting the frequencies into patient numbers also helps to refocus attention 
onto the substantial populations of patients that might benefit from anti-Ras 
therapeutics in cancers where Ras is not frequently mutated. After a prolonged period 
where it seemed that Ras was undruggable, we are now entering an era where it 
seems feasible that we will have Ras-targeted precision therapy options available that 
can be tailored to individual mutations and cancers. The patient number estimates 
give an indication of the size of the pool potentially available for clinical trials. Given 
the isoform-, mutation- and tissue-specific differences in Ras biology that are now 
evident, it will be important to have access to even larger databases with high quality 
sample curation and genome-wide profiling to develop deeper understanding that will 
inform these precision medicine approaches.  
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Figure 1. Overview of Ras data in cancer genetics databases. A. The sampling 
relationship, the number of samples tested, and the number of Ras mutant samples 
identified in each of the publicly accessible databases and data portals. B. The sample 
tissue composition of each database is not equivalent. Data sources: COSMIC v85, 
cBioPortal v2.2.0, ICGC release 27, TCGA release 12.0 all accessed 
contemporaneously.  
 
Table 1. Ras mutation frequency and cancer-associated disease burden. Mutation 
frequencies are based on COSMIC data together with selected publicly available 
COAD (H, K, N), READ (H, K, N), LUAD (K) and PAAD (K) data from the Foundation 
Medicine database (40,41,44). Mutation frequencies are applied to the most recent 
American Cancer Society data on cancer incidence (total patients) to estimate new 
cancer cases per year in the USA. 
 
 
Supplementary Figure 1. Genetic alterations in the RTK/Ras network across cancer 
types. TCGA data was collated based on 85 RTK/RAS-relevant genes listed in 
Supplementary Table 1b. Amplification/deletion represents at least a +2/-2 change in 
copy number. 
 
Supplementary Table 1. Comparison of KRAS mutation frequencies in each 
database. Significant variability in sampling depth and mutation frequency is evident 
between each database. Summary statistics from databases with tissue type 
classification are included together with disease-specific values when available. 
 
Supplementary Table 2. Mutation statistics in major cancer genetics databases. Ras 
isoform mutation data (Table 1a) and copy number variance (CNV) analysis (Table 
1b) are included together with details on how data was collated from COSMIC v85, 
cBioPortal v2.2.0, ICGC release 27 and TCGA release 12.0. 
 
Supplementary Table 3. Ras mutation-specific patterns in cancer. Data are all 
collated from COSMIC v85 and where indicated converted in patient numbers using 
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Figure 1. Overview of Ras data in cancer genetics databases. A. The
sampling relationship, the number of samples tested, and the number of
Ras mutant samples identified in each of the publicly accessible
databases and data portals. B. The sample tissue composition of each
database is not equivalent. Data sources: COSMIC v85, cBioPortal




1,414,644estimated total new cancer cases per year (USA)




















































































































































































































































































































































































































































































Est. no. new patients/year (US )
C.N.S., central nervous system; G.I., gastrointestinal. GBM, glioblastoma multiforme; LGG, lower grade glioma; HNSC, head and
neck squamous cell carcinoma; THCA, papillary thyroid carcinoma; THCAA, anaplastic thyroid carcinoma; THCAF, follicular thyroid
carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BRCA, breast invasive carcinoma; ESCA,
esophageal carcinoma; STAD, stomach adenocarcinoma; SIAD, small intestine adenocarcinoma; COAD, colon adenocarcinoma;
READ, rectal adenocarcinoma; LIHC, liver hepatocellular carcinoma; CHOL, cholangiocarcinoma; GBC, gallbladder carcinoma;
PAAD, pancreatic adenocarcinoma; KIRC, kidney renal clear cell carcinoma; BLCA, bladder urothelial carcinoma; PRAD, prostate
adenocarcinoma; OV, ovarian serous cystadenocarcinoma; UCEC, uterine corpus endometrial carcinoma; CESC, cervical
squamous carcinoma and endocervical adenocarcinoma; SKCM, skin cutaneous melanoma; ALL, acute lymphoblastic leukemia;
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; PCM, plasma cell myeloma.
Table 1. Ras mutation frequency and cancer-associated disease burden. Mutation
frequencies are based on COSMIC data together with selected publicly available COAD (H,
K, N), READ (H, K, N), LUAD (K) and PAAD (K) data from the Foundation Medicine database
(40,41,44). Mutation frequencies are applied to the most recent American Cancer Society















































































































SKCM, skin cutaneous melanoma; UCS, uterine carcinosarcoma; LUAD, lung adenocarcinoma;
LUSC, lung squamous cell carcinoma; BLCA, bladder urothelial carcinoma; ESCA, esophageal
carcinoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma;
THCA, papillary thyroid carcinoma; OV, ovarian serous cystadenocarcinoma; CHOL,
cholangiocarcinoma; HNSC, head and neck squamous cell carcinoma; COAD, colon
adenocarcinoma; GBM, glioblastoma multiforme; CESC, cervical squamous carcinoma and
endocervical adenocarcinoma; PAAD, pancreatic adenocarcinoma; SARC, sarcoma; LIHC, liver
hepatocellular carcinoma; BRCA, breast invasive carcinoma; LAML, acute myeloid leukemia;
DLBC, diffuse large B-cell lymphoma; LGG, lower grade glioma; TGCT, testicular germ cell
cancer; KIRP, papillary kidney carcinoma; PRAD, prostate adenocarcinoma; MESO,













Supplementary Figure 1. Genetic alterations in the RTK/Ras network
across cancer types. TCGA data was collated based on 85 RTK/RAS-
relevant genes listed in Supplementary Table 1b. Amplification/deletion




























































Supplementary Table 1. Comparison of KRAS mutation frequencies in each
database. Significant variability in sampling depth and mutation frequency is evident
between each database. Summary statistics from databases with tissue type



























































































































































































































































































































































































































































































































































































HRAS KRAS NRAS mutation bias
GBM, glioblastoma multiforme; LGG, lower grade glioma; HNSC, head and neck squamous cell carcinoma; THCA,
papillary thyroid carcinoma; THCAA, anaplastic thyroid carcinoma; THCAF, follicular thyroid carcinoma; LUAD,
lung adenocarcinoma; LUSC, lung squamous cell carcinoma; BRCA, breast invasive carcinoma; ESCA,
esophageal carcinoma; STAD, stomach adenocarcinoma; SIAD, small intestine adenocarcinoma; COAD, colon
adenocarcinoma; READ, rectal adenocarcinoma; LIHC, liver hepatocellular carcinoma; CHOL,
cholangiocarcinoma; GBC, gallbladder carcinoma; PAAD, pancreatic adenocarcinoma; KIRC, kidney renal clear
cell carcinoma; BLCA, bladder urothelial carcinoma; PRAD, prostate adenocarcinoma; OV, ovarian serous
cystadenocarcinoma; UCEC, uterine corpus endometrial carcinoma; CESC, cervical squamous carcinoma and
endocervical adenocarcinoma; SKCM, skin cutaneous melanoma; ALL, acute lymphoblastic leukemia; AML, acute






































Supplementary Table 3. Ras mutation-specific patterns in cancer. Data are all collated from COSMIC v85
and where indicated converted in patient numbers using ACS 2018 cancer incidence statistics.
